公开(公告)号：US20060063156A1

公开(公告)日：2006-03-23

申请号：US10729895

申请日：2003-12-05

申请人： Cheryl Willman ,  Paul Helman ,  Robert Veroff ,  Monica Mosquera-Caro ,  George Davidson ,  Shawn Martin ,  Susan Atlas ,  Erik Andries ,  Huining Kang ,  Jonathan Shuster ,  Xuefei Wang ,  Richard Harvey ,  David Haaland ,  Jeffrey Potter

发明人： Cheryl Willman ,  Paul Helman ,  Robert Veroff ,  Monica Mosquera-Caro ,  George Davidson ,  Shawn Martin ,  Susan Atlas ,  Erik Andries ,  Huining Kang ,  Jonathan Shuster ,  Xuefei Wang ,  Richard Harvey ,  David Haaland ,  Jeffrey Potter

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N15/09 ,  C07K14/705

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136

摘要： Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.

公开(公告)号：US20060141504A1

公开(公告)日：2006-06-29

申请号：US11285976

申请日：2005-11-23

申请人： Cheryl Willman ,  Edward Bedrick ,  Huining Kang ,  Paul Helman ,  Robert Veroff

发明人： Cheryl Willman ,  Edward Bedrick ,  Huining Kang ,  Paul Helman ,  Robert Veroff

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention relates to methods for predicting the outcome of therapeutic intervention in cases of leukemia, especially acute lymphoblastic leukemia in children and adults. The present invention evaluates a gene expression profile and identifies prognostic genes of cancers, in particular leukemia, more particularly B-precursor acute lymphoblastic leukemia (ALL). The present invention provides a method of determining prognosis of leukemia, in particular, acute lymphoblastic leukemia, more particularly B-precursor ALL and predicting therapeutic outcome of a patient. The method comprises the steps of first establishing the threshold value of at least three prognostic genes of leukemia, preferably at least eight prognostic genes, or preferably, as many as 26 prognostic genes. Then, the amount of the prognostic gene(s) from a leukemia patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene(s) which is indicative of therapeutic success or failure, whereby the prognostic outcome of the patient is determined/predicted.

摘要翻译： 本发明涉及用于预测儿童和成人白血病尤其是急性淋巴细胞性白血病患者治疗干预结果的方法。 本发明评估基因表达谱并鉴定癌症，特别是白血病，特别是B-前体急性成淋巴细胞白血病（ALL）的预后基因。 本发明提供了一种确定白血病预后的方法，特别是急性淋巴细胞白血病，特别是B-前体ALL预测患者的治疗结果。 该方法包括以下步骤：首先建立至少三种白血病预后基因的阈值，优选至少八个预后基因，或优选多达26个预后基因。 然后，确定来自白血病患者的预后基因的量。 将该患者中存在的预后基因的量与确定/预测患者的预后结果的预后基因的确定阈值进行比较。